The AMR Narrative

Catheter-associated Urinary Tract Infection (CAUTI)

Although great care has been taken in the compilation and preparation of all directory entries to ensure accuracy, we cannot accept responsibility for any errors or omissions. Any medical information is provided for education/information purposes only and is not designed to replace medical advice by a qualified medical professional. Please see our disclaimer at the bottom of this entry.

What is a Catheter-associated Urinary Tract Infection (CAUTI)?

A Urinary Tract Infection (UTI) is an infection of the urinary tract, which includes different organs, such as the kidneys, ureters, bladder, and urethra. UTIs are the most common type of healthcare-associated infection and are often caused by the presence or placement of a catheter in the urinary tract.

A Catheter-associated Urinary Tract Infection (CAUTI) occurs when certain microorganisms (bacteria or fungi) enter the urinary tract through a catheter and cause an infection involving the bladder (cystitis) or even the kidneys (pyelonephritis), for example.

CAUTIs may be difficult to treat because of the increasing resistance of germs to the available antimicrobials. Therefore, CAUTIs are associated with increased mortality, healthcare costs, and length of hospital stay.


What is a urinary catheter?

A urinary catheter is a thin tube placed in the bladder to drain urine into a bag that collects the urine outside the body. This tube may stay in place for a long period of time. If so, it is called an indwelling catheter.

A urinary catheter may be used:

● if you are unable to urinate on your own;
● if you are very ill and cannot control your urine;
● during and right after some types of surgery;
● during some tests of the kidneys and bladder;
● to monitor the amount of urine during intensive care.
People with urinary catheters have a higher risk of developing a UTI than people who do not have a catheter. Moreover, the prolonged use of a urinary catheter is the most important risk factor for developing a CAUTI.


How do patients get a CAUTI?

Microorganisms, such as bacteria or fungi, may cause a CAUTI by entering the urinary tract. Indeed, germs can enter the bladder in several ways: during the insertion of the catheter, through the catheter lumen, or from around the outside of the catheter while the catheter remains in the bladder.
Many of the germs that cause CAUTIs are commonly found in the intestines, but do not usually cause an infection there.


What are the symptoms of a CAUTI?

Some common symptoms and signs of a CAUTI are the following:

● burning or pain in the lower abdomen;
● fever;
● bloody urine, or an abnormal urine colour;
● burning during urination or an increase in the frequency of urination after the catheter is removed.

Sometimes people with CAUTIs do not have these symptoms and signs of infection. Other symptoms that may occur with a CAUTI are chills, flank pain, mental changes or confusion.


How is a CAUTI diagnosed?

To correctly diagnose a CAUTI, first your physician will perform a physical examination and ask you about symptoms. Guided by these elements, your doctor will be able to choose the most appropriate diagnostic tests.

Laboratory tests used to identify a CAUTI are represented by urinalysis and urine culture. A sample of urine is sent to a laboratory to grow the microorganism over time using a media on a petri dish (culture) and identify it. Then susceptibility tests can be carried out to determine which antimicrobials are most effective against it, to start the most appropriate antimicrobial therapy. Understanding which antimicrobials will work best is especially key to CAUTIs as resistance among urinary pathogens is a constantly growing problem.

Finally, depending on the type of infection, your physician may recommend additional tests, such as imaging tests of the abdomen or pelvis.


How is a CAUTI treated?

Guided by the symptoms and the results of diagnostic tests, your physician will determine the best treatment for you. Antimicrobials, such as antibiotics or antifungals, may be used to treat a CAUTI.

The antimicrobials may vary according to the type of the infection, the microorganism responsible of the disease, and the results of susceptibility tests. Depending on the site and the severity of infection, the medications could be in the form of tablets to swallow. However, severe infections require to be treated in hospital with intravenous antimicrobials (the medications are given through a drip or a tube), and additional therapies. Finally, the urinary catheter may be removed or changed.

Unfortunately, due to the increasing resistance to the available antimicrobials, CAUTIs are becoming more and more difficult to treat, and sometimes a combination therapy is needed (it means that two or even more antimicrobials are necessary).


What can patients and caregivers do to help prevent a CAUTI?

Patients with a urinary catheter and their caregivers can take the following precautions to help to prevent a CAUTI.

● Understand why the urinary catheter has been placed.
● Ask frequently your doctor or nurse if you still need the urinary catheter. Indeed, the risk of CAUTI can be reduced by ensuring that catheters are used only when needed, and removed as soon as possible.
● Always clean your hands (by washing them with soap and water or using an alcohol-based hand rub) before and after touching the urinary catheter. Remember: hand hygiene is your best protection against infections.
● Always keep your urine bag below the level of your bladder to prevent urine from backflowing to the bladder.
● Do not tug or pull on the catheter tubing.
● Do not twist or kink the catheter tubing.
● If you suspect to have any symptoms of infection, call your doctor immediately.





Disclaimer: The information provided on this website is intended for educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Reliance on any information provided on this website is solely at your own risk. The website owners and authors are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. It is recommended that you consult a qualified healthcare professional for individualised medical and health-related guidance.

Cameron Prior

Cameron Prior

BVSc MSc PgCert CertAVP DipECVIM-CA MRCVS

RCVS Recognised Specialist in Small Animal Medicine

Cameron is a European Diplomate in Small Animal Internal Medicine. Passionate about fungal disease, antimicrobial stewardship, endocrinopathy, and facilitating multiple studies to enhance the evidence base of veterinary medicine. Keen to build collaborative projects with colleagues across Europe and to promote clinical research in practice.

Abi Mc Alester

Abi Mc Alester

I am a graduate from the National University of Galway with an Honours BSc in Pharmacology, and a recent graduate from Maynooth University with a MSc in Immunology & Global Health. Throughout university, I was an active member of the Global Health Network, which was a student-led group focusing on health, equity, and international development. Here is where I became interested in the global impact of AMR and the multiple factors that influence its spread. I chose to focus my studies on the mechanisms behind resistance and vaccination design; however, I understand that in order to have a global impact, there needs to be global awareness.

The AMR Narrative provides lived experiences and stories from those affected by resistance, something I believe is so important and why I wanted to help share these stories on social media. Translating scientific knowledge into digestible and understandable language is critical for fighting resistance.

Nduta Kamere

Nduta is a global health pharmacist and AMR consultant recognised for her leadership in antimicrobial stewardship, One Health, and healthcare equity. She has shaped AMR strategies and advanced healthcare accessibility across Africa, with a significant portfolio that includes contributions to the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programmes. As Technical Lead, she oversaw the co-development of the Quadripartite Antimicrobial Resistance Toolkit for Youth Engagement, now used globally to drive advocacy and behaviour change.

Her expertise spans supply chains, pricing, and substandard and falsified medicines, and her research is published in the WHO Bulletin and peer-reviewed journals, informing regional and global AMR policy and practice.

Dr Marie-Anne Bouldouyre

Dr Marie-Anne Bouldouyre is an infectious diseases physician and hospital practitioner in Paris. Twelve years of clinical work in a suburban hospital shaped her understanding of access to care, patient relationships, and the daily reality of antimicrobial resistance.

Since 2022, she has led the Regional Antibiotic Stewardship Centre in Île-de-France and coordinates the national network, working with a multidisciplinary team to promote responsible antibiotic use and strengthen collaboration among healthcare professionals. She also continues to manage complex infections at Saint-Louis Hospital.

Convinced that antimicrobial resistance cannot be tackled by healthcare workers alone, she advocates for the active involvement of patients : understanding, questioning, and taking part in decisions about antibiotics. Their stories are essential to making this issue visible and concrete.

She is proud to collaborate with initiatives such as The AMR Narrative and hopes to foster similar projects in France to give patients a voice in this shared fight.

Dr Erva Cinar

Dr Erva Cinar is a London based paediatric resident doctor and clinical researcher with interest in infectious diseases.

She is currently completing a Master’s in Public Health at the London School of Hygiene & Tropical Medicine. Through the World Medical Association’s Junior Doctor’s Network (WMA-JDN) AMR Working Group, she engages in policy and advocacy on antimicrobial resistance and stewardship at global level.

Alongside her clinical and academic roles, she works with the Royal College of Paediatrics and Child Health (RCPCH) and the International Child Health Group (ICHG); leads on organising teaching resources and educational events to improve research skills for UK paediatric trainees and for global child health professionals.

Hamu Madzedze

Hamu Madzedze is a seasoned Zimbabwean journalist with over 15 years’ experience.

She previously worked for the Zimbabwe Broadcasting Corporation as a reporter and sub-editor, before establishing an independent website, 365HealthDiaries, which focuses on health and gender issues.

She holds a BA in Media Studies and a BA (Special Honours) in Communication and Media from the Zimbabwe Open University, as well as a diploma from the Christian College of Southern Africa.

Her work has been recognised with several awards, including the Global AMR Special Mention Award (2024), the Sexual Health Rights and Equity Fellowship Special Mention Award (2025), and the Merck Foundation Award (2024) for outstanding coverage of health issues, gender, infertility, and genital mutilation, where she achieved third position in the Online Category.

Hamu is passionate about addressing AMR through the media.

Jomana F. Musmar

Dr. Jomana Musmar is a distinguished global policy expert and proactive leader with over fifteen years of government experience in strategic planning, operational design, and policy execution. Renowned for simplifying complex topics with expertise and diplomacy, she has spearheaded innovative solutions to global health challenges, shaped impactful policies, and advanced national and international missions.

As the Executive Director of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, she established and led the council’s operations, liaising with over 600 experts, worldwide, across government, industry, and academia. Her efforts culminated in the development of critical recommendations addressing antimicrobial resistance and interrelated One Health issues, influencing both domestic and global health strategies.

In her tenure as Deputy Director of Strategic Initiatives for the Office of Infectious Diseases and HIV/AIDS Policy, at the US Department of Health and Human Services, Dr. Musmar oversaw the formulation and implementation of national health strategies for vaccines and a range of infectious diseases including HIV/AIDS and viral hepatitis. Her leadership and technical expertise facilitated groundbreaking policies during national emergencies, including responses to the COVID-19 pandemic, and initiatives to combat congenital syphilis and childhood vaccination disruptions. Dr. Musmar holds a Ph.D. in Biodefense from George Mason University, a Master’s degree in Biomedical Science policy and Advocacy from Georgetown University, and is a Lean Six Sigma Black Belt. Fluent in English and Arabic, she is a sought-after speaker and advisor, having represented the United States at premier global health conferences.

Her published works on antimicrobial resistance, pandemic preparedness, and national health security underscore her reputation as a thought leader and innovator in public health and biodefense.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.